Azacitidine induces profound genome-wide hypomethylation in primary myelodysplastic bone marrow cultures but may also reduce histone acetylation

Leukemia

Volumn 28, Issue 2, 2014, Pages 411-413

  Grovdal M ^a   Karimi, M ^a   Tobiasson, M ^a   Reinius, L ^b   Jansson, M ^a   Ekwall, K ^b   Ungerstedt, J ^a   Kere, J ^b,c   Greco, D ^b,c   Hellstrom Lindberg E ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLATION; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BONE MARROW CELLS; CELLS, CULTURED; DNA METHYLATION; EPIGENESIS, GENETIC; EPIGENOMICS; HISTONES; HUMANS; MYELODYSPLASTIC SYNDROMES;

EID: 84893799042     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.265     Document Type: Letter

References (15)

1. Fenaux P, Mufti GJ, Hellströ m-Lindberg E, Santini V, Finelli C, Giagounidis A et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomized, open-label, phase III study. Lancet Oncol 2009; 10: 223-232.
2. Fenaux P, Gattermann N, Seymour JF, Hellströ m-Lindberg E, Mufti GJ, Duehrsen U et al. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low-dose ara-C. Br J Haematol 2010; 149: 244-249.
3. Flotho C, Claus R, Batz C, Schneider M, Sandrock I, Ihde S et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute meloid leukemia cells. Leukemia 2009; 23: 1019-1028.
4. Curik N, Burda P, Vargova K, Pospisil V, Belickova M, Vlckova P et al. 5-Azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU. and cell differentiation capacity. Leukemia 2012; 26: 1804-1811.
5. Schmeltz K, Sattler N, Wagner M, Lü bbert M, Tamm I. Induction of gene expression by 5-Aza-2'-deoxycitidine in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) but not epithelial cells by DNAmethylation dependent and-independent mechanisms. Leukemia 2005; 19: 103-111.
6. Khan R, Schmidt-Mende J, Karimi M, Gogvadze V, Hassan M, Ekström TJ et al. Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells. Exp Hematol 2008; 36: 149-157.
7. Sánchez-Abarca LI, Gutierrez-Cosio S, Santamar?́a C, Caballero-Velazquez T, Blanco B, Herrero-Sánchez C et al. Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. Blood 2010; 115: 107-121.
8. Komashko VM, Farnham PJ. 5-azacytidine treatment reorganizes genomic histone modification patterns. Epigenetics 2010; 5: 229-240.
9. Schaefer M, Hagemann S, Hanna K, Lyko K. Azacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell lines. Cancer Res 2009; 69: 8127-8132.
10. Grö vdal M, Karimi M, Khan R, Aggerholm A, Antunovic P, Astermark J et al. Maintenance treatment with azacitidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia following MDS in complete remission after induction chemotherapy. Br J Haematol 2010; 150: 293-302.
11. Yang AS, Doshi KD, Choi SW, Mason JB, Mannari RK, Gharybian V et al. DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. Cancer Res 2006; 66: 5495-5503.
12. Aparicio A, North B, Barske L, Wang X, Bollati V, Weisenberger D et al. LINE-1 methylation is plasma DNA as a biomarker of activity of DNA methylation inhibition in patients with solid tumors. Epigenetics 2009; 4: 20-28.
13. Figueroa ME, Skrabanek L, Li Y, Fandy TE, Paietta E, Fernandez H et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 2009; 114: 3448-3458.
14. Hon GC, Hawkins RD, Caballero OL, Lo C, Lister R, Pelizzola M et al. Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer. Genome Res 2011; 22: 246-258.
15. Romano A, Barresi V, Capizzi C, Giallongo C, Nicolo M, La Cava P et al. Proteomic and genomic profile of high-risk MDS after treatment with 5-azacitidine. ASH annual meeting abstracts Blood 2011; 118: 3818.